Stoke Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Stoke Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q2 2024.
  • Stoke Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$25.7M, a 16.2% increase year-over-year.
  • Stoke Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$104M, a 1.33% increase year-over-year.
  • Stoke Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$105M, a 3.59% decline from 2022.
  • Stoke Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$101M, a 17.8% decline from 2021.
  • Stoke Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$85.8M, a 64.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$104M -$25.7M +$4.96M +16.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$109M -$26.4M -$3.83M -17% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-07
Q4 2023 -$105M -$27M -$1.3M -5.08% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$103M -$24.5M +$1.57M +6.01% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$105M -$30.7M -$6M -24.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$99M -$22.5M +$2.1M +8.54% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-07
Q4 2022 -$101M -$25.7M -$1.21M -4.94% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$99.9M -$26.1M -$3.51M -15.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$96.3M -$24.7M -$2.69M -12.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$93.7M -$24.6M -$7.86M -46.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$85.8M -$24.4M -$9.89M -67.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$75.9M -$22.6M -$8.91M -65.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$67M -$22M -$9.01M -69.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$58M -$16.8M -$5.75M -52.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$52.2M -$14.6M -$4.4M -43.3% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-09
Q3 2020 -$47.8M -$13.7M -$5.08M -59% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$42.8M -$13M -$5.14M -65.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$37.6M -$11M -$5.3M -92.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$32.3M -$10.2M -$5.88M -137% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$26.4M -$8.6M -$5.29M -159% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-09
Q2 2019 -$21.2M -$7.82M -$4.81M -160% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-09
Q1 2019 -$16.4M -$5.74M -$3.83M -200% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-09
Q4 2018 -$12.5M -$4.28M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 -$3.32M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-23
Q2 2018 -$3.01M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-23
Q1 2018 -$1.91M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.